Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797141 | 0.84 | KMT2A (0.39) | KMT2AMEN1HTTSLC6A2SLC6A4 | |
| SCHEMBL16797206 | 0.82 | KMT2A (0.41) | KMT2AMEN1HTTSLC6A2SLC6A4 | |
| SCHEMBL16797182 | 0.80 | SLC6A2 (0.46) | KMT2AHTTDPP4SLC6A2SLC6A4 | |
| SCHEMBL15540477 | 0.79 | DPP4 (0.57) | KMT2AMEN1HTTDPP4SLC6A2 | |
| SCHEMBL16756473 | 0.77 | MEN1 (0.38) | KMT2AMEN1HTTSLC6A2SLC6A4 | |
| SCHEMBL27797008 | 0.76 | HTR2A (0.42) | KMT2AMEN1DPP4ALDH1A1 | |
| SCHEMBL264299 | 0.74 | DRD1 (0.42) | KMT2AMEN1HTTDRD1ALDH1A1 | |
| SCHEMBL29819809 | 0.74 | DRD1 (0.42) | KMT2AMEN1HTTDRD1ALDH1A1 | |
| SCHEMBL28879840 | 0.73 | TAAR1 (0.42) | DPP4SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL2031163 | 0.73 | HTT (0.41) | KMT2AMEN1HTTSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125389-A1 | MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| CN-119894902-A | Membrane associated tyrosine and threonine kinase inhibitors and uses thereof | 海南先声再明医药股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125389-A1 | MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF | PKMYT1, PKN1, ROS1 | KMT2A 930/4885MEN1 1426/4885HTT 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.